Leptin and cardiovascular disease response to therapeutic interventions

Circulation

Volumn 117, Issue 25, 2008, Pages 3238-3249

  Koh, Kwang Kon ^a   Park, Sang Min ^a   Quon, Michael J ^b  

^a Gachon University College of Medicine   (South Korea)

^b National Institutes of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANTIDIABETIC AGENT; ATENOLOL; ATORVASTATIN; BROMOCRIPTINE; BUNAZOSIN; CANDESARTAN; CARDIOVASCULAR AGENT; DEXAMETHASONE; FELODIPINE; FENOFIBRATE; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; INSULIN; LEPTIN; LIPID; LOSARTAN; METFORMIN; METYRAPONE; MEVINOLIN; PERINDOPRIL; PINDOLOL; PLACEBO; RAMIPRIL; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADIPOCYTE; ATHEROGENESIS; ATHEROSCLEROSIS; BIOLOGY; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; HORMONE METABOLISM; HUMAN; HYPERLEPTINEMIA; INSULIN RESISTANCE; INTERVENTION STUDY; LIFESTYLE MODIFICATION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; THROMBOSIS; TREATMENT RESPONSE; ANIMAL; DIABETES MELLITUS; DRUG COMBINATION; GENETICS; HYPERTENSION; METABOLISM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; OBESITY;

EID: 51649124024     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.741645     Document Type: Review

References (120)

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432.
2. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26:1407-1433.
3. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes. 2004;53(suppl 1):S152-S158.
4. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189: 47-60.
5. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2004;13:215-223.
6. Werner N, Nickenig G. From fat fighter to risk factor: the zigzag trek of leptin. Arterioscler Thromb Vasc Biol. 2004;24:7-9.
7. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens. 2006;24:789-801.
8. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28:463-491.
9. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-657.
10. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904.
11. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Op Lipidol. 2007;18:58-65.
12. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052-3056.
13. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, Colombo A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003;108:2074-2081.
14. Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L, Hallmans G, Olsson T. Leptin is a risk marker for first-ever hemor- rhagic stroke in a population-based cohort. Stroke. 1999;30:328 -337.
15. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, Kitagawa M, Kondo K, Chait A, Shimokado K. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis. 2008;196:68-75.
16. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N. Severe hypercholesterolemia, hyper- triglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001;276:37402-37408.
17. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose- intolerant women: impact on cardiovascular mortality. Diabetes Care. 2003;26:2883-2889.
18. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007; 49:531-538.
19. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens. 2002;20:1245-1250.
20. Ke Chen, Fanghong Li, Ji Li, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ. Induction of leptin resistance through direct interaction of C-reactiveprotein with leptin. Nat Med. 2006;12:425-432.
21. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27:710-718.
22. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, Trimarco B. Leptin induces direct vasodilation through distinct endo- thelial mechanisms. Diabetes. 2000;49:293-297.
23. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005;26:33-65.
24. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44(pt 2):1809 -1819.
25. Knudson JD, Dincer UD, Zhang C, Swafford AN Jr, Koshida R, Picchi A, Focardi M, Dick GM, Tune JD. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary en- dothelial dysfunction. Am J Physiol. 2005;289:H48-H56.
26. Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J. High serum leptin is associated with attenuated coronary vasoreactivity. Obes Res. 2003;11:776-782.
27. Porreca E, Di Febbo C, Fusco L, Moretta V, Di Nisio M, Cuccurullo F. Soluble thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women. Atherosclerosis. 2004; 172:175-180.
28. Koh KK, Quon MJ, Lee SJ, Han SH, Ahn JY, Kim JA, Chung WJ, Lee Y, Shin EK. Efonidipine simultaneously improves blood pressure, en- dothelial function, and metabolic parameters in non-diabetic patients with hypertension. Diabetes Care. 2007;30:1605-1607.
29. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002;106:1919 -1924.
30. Koh KK, Quon MJ, Han SH, Han SH, Ahn JY, Chung WJ, Kim JA, Shin EK. Additive beneficial cardiovascular and metabolic effects of combi nation therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007;28:1440-1447.
31. Maingrette F, Renier G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes. 2003;52:2121-2128.
32. O'Rourke L, Yeaman SJ, Shepherd PR. Insulin and leptin acutely regulate cholesterol ester metabolism in macrophages by novel signaling pathways. Diabetes. 2001;50:955-961.
33. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR. Glucose- dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem. 2002;277:42557-42562.
34. Rainwater DL, Comuzzie AG, VandeBerg JL, Mahaney MC, Blangero J. Serum leptin levels are independently correlated with two measures of HDL. Atherosclerosis. 1997;132:237-243.
35. Lundasen T, Liao W, Angelin B, Rudling M. Leptin induces the hepatic high density lipoprotein receptor scavenger receptor B type I (SR-BI) but not cholesterol 7-hydroxylase (Cyp7a1) in leptin deficient (ob/ob) mice. J Biol Chem. 2003;278:43224-43228.
36. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12: 57-65.
37. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001;276:25096-25100.
38. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol. 2003;133:11-19.
39. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999;56:860-872.
40. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes. 2005;54:2227-2234.
41. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1 dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther. 2005; 315:1075-1084.
42. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002;90:711-718.
43. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001;88:954-960.
44. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos. 1999;27:695-700.
45. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma para- oxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis. 2003;170:21-29.
46. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension. 2006;47:222-229.
47. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V. Paraoxonase activity in high-density lipoproteins: a com parison between healthy and obese females. J Clin Endocrinol Metab. 2005;90:1728-1733.
48. Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R, Eigenthaler M, Lohmann T. Differences in platelet activation by prolactin and leptin. Horm Metab Res. 2004;36:453-457.
49. Corsonello A, Perticone F, Malara A, De Domenico D, Loddo S, Buemi M, Ientile R, Corica F. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord. 2003; 27:566-573.
50. Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir IC, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res. 2001;9:627-630.
51. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288:2008 -2014.
52. Thogersen AM, Soderberg S, Jansson JH, Dahlén G, Boman K, Nilsson TK, Lindahl B, Weinehall L, Stenlund H, Lundberg V, Johnson O, Ahrén B, Hallmans G. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2004;11:33-40.
53. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis. 2001;157:495-503.
54. Soderberg S, Olsson T, Eliasson M, Johnson O, Ahren B. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med. 1999;245:533-543.
55. Malyszko J, Wolczynski S, Malyszko J, Mysliwiec M. Leptin correlates with some hemostatic parameters in CAPD patients. Nephron. 2002;92: 721-724.
56. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2 dependent pathway. Obes Res. 2005;13:969-973.
57. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology. 2004;145:169-174.
58. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens. 1998;16:1475-1480.
59. Adamczak M, Kokot F, Wiecek AW. Relationship between plasma rennin profile and leptinaemia in patients with essential hypertension. J Hum Hypertens. 2000;14:503-509.
60. Correia ML, Morgan DA, Sivitz WI, Mark AL, Haynes WG. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 2001;37:936-942.
61. Vecchione C, Aretini A, Maffei A, Marino G, Selvetella G, Poulet R, Trimarco V, Frati G, Lembo G. Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension. 2003;42:166-170.
62. Mitchell JL, Morgan DA, Correia ML, Mark AL, Sivitz WI, Haynes WG. Does leptin stimulate nitric oxide to oppose the effects of sympathetic activation? Hypertension. 2001;38:1081-1086.
63. Jalali A, Morgan DA, Sivitz WI, Correia ML, Mark AL, Haynes WG. Does leptin cause functional peripheral sympatholysis? Am J Hypertens. 2001;14:615-618.
64. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology. 1997;138: 3395-3401.
65. de Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, Dowse G, Alberti KG. Hyperleptinaemia: the missing link in the metabolic syndrome? Diabet Med. 1997;14:200-208.
66. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996;274:1185-1188.
67. Hennige AM, Stefan N, Kapp K, Lehmann R, Weigert C, Beck A, Moeschel K, Mushack J, Schleicher E, Häring HU. Leptin down- regulates insulin action through phosphorylation of serine-318 in insulinreceptor substrate 1. FASEB J. 2006;20:1206-1208.
68. Muoio DM, Dohm GL, Fiedorek FT, Tapscott EB, Coleman RA. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes. 1997;46: 1360 -1363.
69. Liu Y-L, Emilsson V, Cawthorne MA. Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob = ob) mice. FEBS Lett.1997;411: 351-355.
70. Berti L, Kellerer M, Capp E, Haring HU. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes; evidence for aPI3-kinase mediated effect. Diabetologia. 1997;40:606-609.
71. Beltowski J, Wojcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci. 2004;74:2987-3000.
72. Correia ML, Morgan DA, Mitchell JL, Sivitz WI, Mark AL, Haynes WG. Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure. Hypertension. 2001;38: 384-388.
73. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997;10:1171-1174.
74. Mallamaci F, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tripepi R, Zoccali C. Gender-dependent differences in plasma leptin in essential hypertension. Am J Hypertens. 2000;13:914-920.
75. Soderberg S, Ahren B, Jansson JH, Sjöström LG, Agren A, Johansson L, Weinehall L, Olsson T. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246:409 -418.
76. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Press. 2004;13: 243-246.
77. Makris TK, Hatzizacharias AN, Krespi PG, Chronakis EV, Vythoulkas JS, Maria K, Tsoukala CG, Votteas VV. Markers of risk in young offspring with paternal history of myocardial infarction. Int J Cardiol. 2003;89:287-293.
78. Soderberg S, Stegmayr B, Stenlund H, Sjostrom LG, Agren A, Johansson L, Weinehall L, Olsson T. Leptin, but not adiponectin, predicts stroke in males. J Intern Med. 2004;256:128-136.
79. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, Giorgino R, De Pergola G. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord. 2001;25:805-810.
80. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002;106:1919-1924.
81. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25-31.
82. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes. 2004;112:378 -382.
83. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ, Després JP. Leptinemia is not a risk factor for ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Diabetes Care. 1998;21:782-786.
84. McNeely MJ, Boyko EJ, Weigle DS, Shofer JB, Chessler SD, Leonnetti DL, Fujimoto WY. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care. 1999;22:65-70.
85. Soderberg S, Zimmet P, Tuomilehto J, Chitson P, Gareeboo H, Alberti KG, Shaw JE. Leptin predicts the development of diabetes in Mauritian men, but not women: a population-based study. Int J Obes (Lond). 2007;31:1126-1133.
86. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007;30:1200-1205.
87. Ruige JB, Dekker JM, Blum WF, Stehouwer CD, Nijpels G, Mooy J, Kostense PJ, Bouter LM, Heine RJ. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study: the Hoorn Study. Diabetes Care. 1999;22:1097-1104.
88. Flanagan DE, Vaile JC, Petley GW, Phillips DI, Godsland IF, Owens P, Moore VM, Cockington RA, Robinson JS. Gender differences in the relationship between leptin, insulin resistance and the autonomic nervous system. Regul Pept. 2007;140:37-42.
89. Menendez C, Baldelli R, Lage M, Casabiell X, Piñero V, Solar J, Dieguez C, Casanueva FF. The in vitro secretion of human leptin is gender-dependent but independent of the body mass index of the donors. Eur J Endocrinol. 2000;143:711-714.
90. Torgerson JS, Carlsson B, Stenlof K Carlsson LM, Bringman E, Sjostrom L. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab. 1999;84:4197-4203.
91. Geldszus R, Mayr B, Horn R Geisthövel F, von zur Muhlen A, Brabant G. Serum leptin and weight reduction in female obesity. Eur J Endo- crinol. 1996;135:659-662.
92. Winnicki M, Somers VK, Accurso V, Phillips BG, Puato M, Palatini P, Pauletto P. Fish-rich diet, leptin, and body mass. Circulation. 2002;106: 289 -291.
93. Oral EA, Simha V, Ruiz E Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin- replacement therapy for lipodystrophy. N Engl J Med. 2002;346: 570-578.
94. Uckaya G, Ozata M, Sonmez A, Kinalp C, Eyileten T, Bingol N, Koc B, Kocabalkan F, Ozdemir IC. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res. 1999;31:435-438.
95. Umeda M, Kanda T, Murakami M. Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res. 2003;26:485-492.
96. Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Koca- balkan F, Ozata M. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J Renin Angio- tensin Aldosterone Syst. 2001;2:112-116.
97. Ficek J, Kokot F, Chudek J, Adamczak M, Ficek R, Wiecek A. Influence of antihypertensive treatment with perindopril, pindolol or felodipin on plasma leptin concentration in patients with essential hypertension. Horm Metab Res. 2002;34:703-708.
98. Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005;28:209 -214.
99. Koh KK, Quon MJ, Han SH. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Circulation. 2006;114: II-677. Abstract.
100. Zhao SP, Wu ZH. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta. 2005;360:133-140.
101. Gannage-Yared MH, Azar RR, Amm-Azar M, Khalife S, Germanos- Haddad M, Neemtallah R, Halaby G. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism. 2005;54:947-951.
102. Hung YJ, Pei D, Wu DA, Kuo SW, Fuh MM, Jeng C. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol. J Formos Med Assoc. 1999;98:104 -110.
103. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 1996;93:5793-5796.
104. Toruner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Akturk M, Karakoc A, Ayvaz G, Arslan M. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Horm Metab Res. 2004;36:226-230.
105. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358 -3370.
106. Ihara S, Shimamoto K, Watanabe H, Sakai R, Kawana M. An alpha1- receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. Hypertens Res. 2006;29:805-811.
107. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P. Met- formin reduces weight, centripetal obesity, insulin, leptin, and low- density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50:856-861.
108. Kok P, Roelfsema F, Frölich M, van Pelt J, Meinders AE, Pijl H. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women. JClin Endocrinol Metab. 2006;91:3236-3240.
109. Askari H, Liu J, Dagogo-Jack S. Hormonal regulation of human leptin in vivo: effects of hydrocortisone and insulin. Int J Obes Relat Metab Disord. 2000;24:1254-1259.
110. Putignano P, Brunani A, Dubini A, Bertolini M, Pasquali R, Cavagnini F; "Study Group on Obesity" of the Italian Society of Endocrinology. Effect of small doses of dexamethasone on plasma leptin levels in normal and obese subjects: a dose-response study. J Endocrinol Invest. 2003;26:111-116.
111. Dagogo-Jack S, Tykodi G, Umamaheswaran I. Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans. J Clin Endocrinol Metab. 2005;90:5333-5335.
112. Reseland JE, Mundal HH, Hollung K, Haugen F, Zahid N, Anderssen SA, Drevon CA. Cigarette smoking may reduce plasma leptin concentration via catecholamines. Prostaglandins Leukot Essent Fatty Acids. 2005;73:43-49.
113. Takekoshi K, Motooka M, Isobe K, Nomura F, Manmoku T, Ishii K, Nakai T. Leptin directly stimulates catecholamine secretion and synthesis in cultured porcine adrenal medullary chromaffin cells. Biochem Biophys Res Commun. 1999;261:426-431.
114. Li MD, Kane JK. Effect of nicotine on the expression of leptin and forebrain leptin receptors in the rat. Brain Res. 2003;991:222-231.
115. Eliasson B, Smith U. Leptin levels in smokers and long-term users of nicotine gum. Eur J Clin Invest. 1999;29:145-152.
116. Hollung K, Rise CP, Drevon CA, Reseland JE. Tissue-specific regulation of leptin expression and secretion by all-trans retinoic acid. J Cell Biochem. 2004;92:307-315.
117. Kabir M, Guerre-Millo M, Laromiguiere M, Slama G, Rizkalla SW. Negative regulation of leptin by chronic high-glycemic index starch diet. Metabolism. 2000;49:764-769.
118. Reseland JE, Haugen F, Hollung K, Solvoll K, Halvorsen B, Brude IR, Nenseter MS, Christiansen EN, Drevon CA. Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res. 2001;42: 743-750.
119. Peyron-Caso E, Taverna M, Guerre-Millo M, Véronèse A, Pacher N, Slama G, Rizkalla SW. Dietary (n-3) polyunsaturated fatty acids up-regulate plasma leptin in insulin-resistant rats. J Nutr. 2002;132:2235-2240.
120. Kratz M, von Eckardstein A, Fobker M, Buyken A, Posny N, Schulte H, Assmann G, Wahrburg U. The impact of dietary fat composition on serum leptin concentrations in healthy nonobese men and women. J Clin Endocrinol Metab. 2002;87:5008-5014.